The control group (N = 141) consisted of refractory/relapsed DLBCL and DHL/THL patients with at least two rituximab-containing therapy lines and known TP53 status either within the framework of routine work-up or from our patient cohort already published [8]. Here, TP53 is linked to diffuse large B-cell lymphoma.